Clinical trial
Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced…
NCT00193453 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00193453 |
|---|---|
| Title | Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer |
| Official title | A Phase II Trial of First-Line Therapy With Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Stage III or IV Non-Small Cell Lung Cancer |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | Gemcitabine, Docetaxel, Cetuximab |
| Enrollment | 69 |
| Start date | Jul 1, 2005 |
| Primary completion | Feb 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Sep 19, 2005 |
| Last update posted | Nov 13, 2012 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: